StockMacro
Company, fund or insider

Help

Menu

Sensus Healthcare

$2.26 -29% in 6 monthsMarket cap $37.2M

SRTS on XNAS, Health Care, Sensus Healthcare, Inc, job postings

Measures activity, not value. Not investment advice.

Revenue fell 53% to $16.6M and the stock is down 42% in a year, but insiders bought $260K.

  • BadNet loss $16M over 12 months, with free cash outflow $11.5M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
60
Website
sensushealthcare.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $6.0M, net loss $1.5M.
Quarter to 31 Dec 2021: revenue $13.0M, net income $5.3MQuarter to 31 Dec 2021: revenue $13.0M, net income $5.3MQuarter to 31 Mar 2022: revenue $10.3M, net income $16.1MQuarter to 31 Mar 2022: revenue $10.3M, net income $16.1MQuarter to 30 Jun 2022: revenue $12.1M, net income $3.5MQuarter to 30 Jun 2022: revenue $12.1M, net income $3.5MQuarter to 30 Sep 2022: revenue $9.0M, net income $1.8MQuarter to 30 Sep 2022: revenue $9.0M, net income $1.8MQuarter to 31 Dec 2022: revenue $13.1M, net income $2.8MQuarter to 31 Dec 2022: revenue $13.1M, net income $2.8MQuarter to 31 Mar 2023: revenue $3.4M, net income -$1.9MQuarter to 31 Mar 2023: revenue $3.4M, net income -$1.9MQuarter to 30 Jun 2023: revenue $4.5M, net income -$380KQuarter to 30 Jun 2023: revenue $4.5M, net income -$380KQuarter to 30 Sep 2023: revenue $3.9M, net income -$1.5MQuarter to 30 Sep 2023: revenue $3.9M, net income -$1.5MQuarter to 31 Dec 2023: revenue $12.6M, net income $4.2MQuarter to 31 Dec 2023: revenue $12.6M, net income $4.2MQuarter to 31 Mar 2024: revenue $10.7M, net income $2.3MQuarter to 31 Mar 2024: revenue $10.7M, net income $2.3MQuarter to 30 Jun 2024: revenue $9.2M, net income $1.6MQuarter to 30 Jun 2024: revenue $9.2M, net income $1.6MQuarter to 30 Sep 2024: revenue $8.8M, net income $1.2MQuarter to 30 Sep 2024: revenue $8.8M, net income $1.2MQuarter to 31 Dec 2024: revenue $13.1M, net income $1.5MQuarter to 31 Dec 2024: revenue $13.1M, net income $1.5MQuarter to 31 Mar 2025: revenue $8.3M, net income -$2.6MQuarter to 31 Mar 2025: revenue $8.3M, net income -$2.6MQuarter to 30 Jun 2025: revenue $7.3M, net income -$1.0MQuarter to 30 Jun 2025: revenue $7.3M, net income -$1.0MQuarter to 30 Sep 2025: revenue $6.9M, net income -$943KQuarter to 30 Sep 2025: revenue $6.9M, net income -$943KQuarter to 31 Dec 2025: revenue $4.9M, net income -$3.2MQuarter to 31 Dec 2025: revenue $4.9M, net income -$3.2MQuarter to 31 Mar 2026: revenue $3.4M, net income -$2.6MQuarter to 31 Mar 2026: revenue $3.4M, net income -$2.6MQuarter to 30 Jun 2026: revenue $2.3M, net income -$8.7MQuarter to 30 Jun 2026: revenue $2.3M, net income -$8.7MQuarter to 30 Sep 2026: revenue $6.0M, net income -$1.5MQuarter to 30 Sep 2026: revenue $6.0M, net income -$1.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $16.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$6.0M-$1.5M
30 Jun 2026$2.3M-$8.7M
31 Mar 2026$3.4M-$2.6M
31 Dec 2025$4.9M-$3.2M
30 Sep 2025$6.9M-$943K
30 Jun 2025$7.3M-$1.0M
31 Mar 2025$8.3M-$2.6M
31 Dec 2024$13.1M$1.5M
30 Sep 2024$8.8M$1.2M
30 Jun 2024$9.2M$1.6M
31 Mar 2024$10.7M$2.3M
31 Dec 2023$12.6M$4.2M
30 Sep 2023$3.9M-$1.5M
30 Jun 2023$4.5M-$380K
31 Mar 2023$3.4M-$1.9M
31 Dec 2022$13.1M$2.8M
30 Sep 2022$9.0M$1.8M
30 Jun 2022$12.1M$3.5M
31 Mar 2022$10.3M$16.1M
31 Dec 2021$13.0M$5.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $16.6M $35.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -53% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$16.0M -$3.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.97 -$0.18
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 41.8% 48.0% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -74.0% -15.3% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -96.5% -8.4% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -37.0% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$11.5M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $12.9M $24.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$12.9M (net cash) -$24.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.15
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.2 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.5 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.0 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Sensus HealthcareSRTS (this company) $37.2Mloss2.2-53%-96.5%
Spectral AIMDAI $33.5Mloss2.3-38%-70.5%
DaxorDXR $43.5M––––
TELA BioTELA $31.1Mloss0.40+1.5%-53.6%
RenovoRxRNXT $45.5Mloss16.4–-469%
Microbot MedicalMBOT $45.7Mloss–––

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$824K

bought $824K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-5.3%

36 13F filers vs 38

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

22%

3.5M shares held by 13F filers (30 Sep 2026) of 16.5M outstanding (10 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.4%

222K shares sold short (30 Oct 2026) of 16.5M outstanding (10 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.2

222K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-3.3%

230K shares sold short in the report before, 222K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

15%

15% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$35K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

19

19 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

19 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Insider buying $260K, 3 insiders

Price $2.26 on 20 Nov 2026, -42% over 12 months (12-month range $2.26 to $5.30)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $836K in the last 12 months (the 12 months before: $160K).
Revenue per quarter. Revenue $6.0M in the latest quarter, -13% on a year earlier.
Capital spending per quarter. Capital spending $5K in the latest quarter, +25% on a year earlier.
Institutional holders (13F filers). 36 13F filers reported holding it in the latest 13F quarter, -7.7% on a year earlier.
Lobbying spend. Lobbying spend: $35K published in the last 12 months, -59% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Nov 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 260K)
6 Feb 2026Lobbying filinglobbying engagement terminated (CAPITOL ADVOCACY & GOVERNMENT AFFAIRS, LLC)
20 Jan 20268-K and other filingsChanged its auditor
17 Jan 2026Lobbying filinglobbying engagement terminated (BRIAN GLACKIN & ASSOCIATES LLC)
10 Jan 20268-K and other filingsDirector or officer change
21 Nov 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 120K)
13 Nov 20258-K and other filingsDirector or officer change
13 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jul 2025Lobbying filingnew lobbying registration (BRIAN GLACKIN & ASSOCIATES LLC)
9 Jul 2025Lobbying filingnew lobbying registration (CAPITOL ADVOCACY & GOVERNMENT AFFAIRS, LLC)
4 Mar 2025Sharp changeShort interest spike: short interest spike, 1.2M vs usual 458K (2025-02-14); 23.8x the same period a year earlier
18 Feb 2025Sharp changeShort interest spike: short interest spike, 1.5M vs usual 445K (2025-01-31); 41.1x the same period a year earlier
28 Jan 2025Sharp changeShort interest spike: short interest spike, 1.4M vs usual 439K (2025-01-15); 34.6x the same period a year earlier
14 Jan 2025Sharp changeShort interest spike: short interest spike, 1.2M vs usual 424K (2024-12-31); 35.3x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 536K vs usual 67K (2024-10-31); 9.8x the same period a year earlier
29 Oct 2024Sharp changeShort interest spike: short interest spike, 586K vs usual 60K (2024-10-15); 22.5x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 532K vs usual 54K (2024-09-30); 11.4x the same period a year earlier
11 Sep 20248-K and other filingsChanged its auditor
31 May 20248-K and other filingsDirector or officer change
31 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Feb 20248-K and other filingsDirector or officer change
18 Jan 20248-K and other filingsDirector or officer change
18 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Sep 20238-K and other filingsA major agreement ended
6 Jun 20238-K and other filingsDirector or officer change
6 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 May 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 138K)
9 Jan 20238-K and other filingsDirector or officer change
9 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jan 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 388K (2022-12-15); 14.5x the same period a year earlier
13 Dec 2022Sharp changeShort interest spike: short interest spike, 1.4M vs usual 379K (2022-11-30); 13.7x the same period a year earlier
15 Nov 2022Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 3.50 (2022-09-30); 30.0x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 524K vs usual 114K (2022-05-13); 6.5x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 513K vs usual 104K (2022-04-14); 7.5x the same period a year earlier
29 Mar 2022Sharp changeQuarterly revenue change: quarterly revenue change, 13.0M vs usual 4.1M (2021-12-31); 2.6x the same period a year earlier
3 Mar 20228-K and other filingsCompleted an acquisition or asset sale
15 Feb 2022Sharp changeMany funds opening a new position: many funds opening a new position, 20 vs usual 2 (2021-12-31)
31 Jan 20228-K and other filingsDirector or officer change
31 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$1.2M published
Month from 1 Mar 2022: -$1.5M published
Month from 1 May 2022: -$75K published
Month from 1 Aug 2022: -$2.9M published
Month from 1 Sep 2022: -$592K published
Month from 1 May 2023: $138K published
Month from 1 Jun 2023: $29K published
Month from 1 Aug 2023: $45K published
Month from 1 Sep 2023: $29K published
Month from 1 May 2024: -$123K published
Month from 1 Feb 2025: $9K published
Month from 1 Aug 2025: $3K published
Month from 1 Nov 2025: $148K published
Month from 1 Feb 2026: $8K published
Month from 1 May 2026: $5K published
Month from 1 Aug 2026: $338K published
Month from 1 Sep 2026: $226K published
Month from 1 Nov 2026: $260K published
Revenue per quarter
Quarter ended 31 Dec 2021: $13.0M, +156% on a year earlier; public on 26 Mar 2022
Quarter ended 31 Mar 2022: $10.3M, +237% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $12.1M, +123% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $9.0M, +63% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $13.1M, +0.6% on a year earlier; public on 24 Mar 2023
Quarter ended 31 Mar 2023: $3.4M, -67% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $4.5M, -63% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $3.9M, -57% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $12.6M, -4.1% on a year earlier; public on 16 Mar 2024
Quarter ended 31 Mar 2024: $10.7M, +212% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $9.2M, +104% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $8.8M, +127% on a year earlier; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $13.1M, +4.0% on a year earlier; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $8.3M, -22% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $7.3M, -21% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $6.9M, -22% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $4.9M, -62% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $3.4M, -59% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $2.3M, -69% on a year earlier; public on 15 Aug 2026
Quarter ended 30 Sep 2026: $6.0M, -13% on a year earlier; public on 14 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $38K, -63% on a year earlier; public on 26 Mar 2022
Quarter ended 31 Mar 2022: $44K, -45% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $45K, +543% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $60K, +1900% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $10K, -74% on a year earlier; public on 24 Mar 2023
Quarter ended 31 Mar 2023: $189K, +330% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $29K, -36% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $11K, -82% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Mar 2024: $233K, +23% on a year earlier; public on 11 May 2024
Quarter ended 31 Mar 2025: $7K, -97% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $27K; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $4K; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $158K; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $3K, -57% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $8K, -70% on a year earlier; public on 15 Aug 2026
Quarter ended 30 Sep 2026: $5K, +25% on a year earlier; public on 14 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 38; public on 14 Feb 2022
31 Mar 2022 report: 52; public on 16 May 2022
30 Jun 2022 report: 53; public on 15 Aug 2022
30 Sep 2022 report: 75; public on 14 Nov 2022
31 Dec 2022 report: 60; public on 14 Feb 2023
31 Mar 2023 report: 59; public on 15 May 2023
30 Jun 2023 report: 45; public on 14 Aug 2023
30 Sep 2023 report: 37; public on 14 Nov 2023
31 Dec 2023 report: 36; public on 14 Feb 2024
31 Mar 2024 report: 41; public on 15 May 2024
30 Jun 2024 report: 44; public on 14 Aug 2024
30 Sep 2024 report: 49; public on 14 Nov 2024
31 Dec 2024 report: 65; public on 14 Feb 2025
31 Mar 2025 report: 51; public on 15 May 2025
30 Jun 2025 report: 43; public on 14 Aug 2025
30 Sep 2025 report: 39; public on 14 Nov 2025
31 Dec 2025 report: 45; public on 17 Feb 2026
31 Mar 2026 report: 41; public on 15 May 2026
30 Jun 2026 report: 38; public on 14 Aug 2026
30 Sep 2026 report: 36; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jul 2025: $20K published
Quarter from 1 Oct 2025: $65K published
Quarter from 1 Jan 2026: $35K published

What is unusual now

  • Made public in the last 90 days: it had 3 insiders buy $260K of its shares on the open market within 30 days (3 filings).
  • Clustered insider buying: had 3 insiders buy $260K of its shares on the open market within 30 days (3 filings) Public on 19 Nov 2026.
  • Revenue per quarter: Revenue $6.0M in the latest quarter, -13% on a year earlier.
  • Capital spending per quarter: Capital spending $5K in the latest quarter, +25% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: no sales; 6 purchases, $665K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Eric SachettaDirectorBuy81,575$2.24$183KForm 4
19 Nov 2026Megan CornishDirectorBuy2,200$2.28$5KForm 4
17 Nov 2026Joseph C SardanoCHIEF EXECUTIVE OFFICERBuy30,000$2.40$72KForm 4
31 Aug 2026Eric SachettaDirectorBuy64,841$3.48$226KForm 4
28 Aug 2026Eric SachettaDirectorBuy20,633$3.23$67KForm 4
25 Aug 2026Eric SachettaDirectorBuy34,697$3.25$113KForm 4
24 Aug 2026Eric SachettaDirectorBuy31,000$3.16$98KForm 4
24 Aug 2026Joseph C SardanoCHIEF EXECUTIVE OFFICERBuy20,000$3.02$60KForm 4

36 institutions reported shares at the end of Q3 2026, 22% of the shares outstanding; 4 opened a position, 5 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Pacific Ridge Capital Partners, LLC784K4.76%$2.3M-5,336-0.7%
Vanguard Capital Management LLC660K4.01%$2.0MNo change
Dimensional Fund Advisors LP301K1.83%$900K-15K-4.8%
Divisadero Street Capital Management, LP278K1.69%$833KNo change
Renaissance Technologies LLC230K1.39%$687K-13K-5.2%
Geode Capital Management, LLC154K0.94%$461KNo change
Greenline Wealth Management LLC149K0.90%$445K+20K+16%
UBS Group AG143K0.87%$428K-9,427-6.2%
North Star Investment Management Corp.126K0.76%$376KNo change
Bank of New York Mellon Corp102K0.62%$304K+1,236+1.2%

Company events

All 31 company events

In 12 months: 1 director or officer change, 1 auditor change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
5 Jun 2026Signed a major agreement8-K
20 Jan 2026Changed its auditor8-K
9 Jan 2026Director or officer change8-K
13 Nov 2025Director or officer change8-K
11 Sep 2024Changed its auditor8-K
30 May 2024Director or officer change8-K
2 Feb 2024Director or officer change8-K
18 Jan 2024Director or officer change8-K

Reported lobbying spend: $35K in Q4 2025, $65K in Q3 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2025EndedBrian Glackin & Associates LLCfor Capitol Advocacy & Government Affairs, LLC (On Behalf Of Sensus Healthcare)Skin cancer treatment and prevention issues.Health issuesFiling
3 Nov 2025EndedCapitol Advocacy & Government Affairs, LLCfor Sensus Healthcare, Inc.medicare fee schedule and coverage for skin cancer treatmentsHealth issuesFiling
9 Jun 2025NewBrian Glackin & Associates LLCfor Capitol Advocacy & Government Affairs, LLC (On Behalf Of Sensus Healthcare)Skin cancer treatment and prevention issues.Health issuesFiling
9 Jun 2025NewCapitol Advocacy & Government Affairs, LLCfor Sensus Healthcare, Inc.skin cancer treatment and prevention issuesHealth issuesFiling
15 Apr 2020NewBallard Partnersfor Sensus HealthcareHealthcare technology policy.Health issues, Government issuesFiling
5 Nov 2019EndedBallard Partnersfor Sensus HealthcareHealthcare technology regulation - physician reimbursement from MedicareHealth issues, Medicare/MedicaidFiling
1 Aug 2016EndedMcdermott+ LLCfor Sensus HealthcareNot statedFiling
1 Jan 2015EndedMcdermott Will & Schulte LLPfor Sensus HealthcareNot statedFiling

The 5 newest of 50 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

13 Dec 2022confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Sensus Healthcare (SRTS): saw 30 13F filers open a new position in the quarter ended 30 Sep 2022, 30× the same quarter last year, while it had 1.5M shares sold short in the 15 Dec 2022 report, 14× the same report last year. Two unrelated kinds of activity within 49 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2022
  • Short interest and volume: Short interest spike, became public on 10 Dec 2022
  • Short interest and volume: Short interest spike, became public on 28 Dec 2022
2020-09-30: 12020-12-31: 02021-03-31: 62021-06-30: 12021-09-30: 12021-12-31: 202022-03-31: 162022-06-30: 92022-09-30: 30
The quarter ended 30 Sep 2022 against the 8 quarters before it. this quarterearliernormal: 3.5
See the evidence (3 changes)

Institutional holdings: Many funds opening a new position became public on 14 Nov 2022

Sensus Healthcare saw 30 13F filers open a new position in the quarter ended 30 Sep 2022, 30× the same quarter last year.

This period
30 (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
3.5
Typical spread (median absolute deviation)
3
How far from its usual level
+6.0
Same quarter last year
1
History used
2,283 days
2020-09-30: 12020-12-31: 02021-03-31: 62021-06-30: 12021-09-30: 12021-12-31: 202022-03-31: 162022-06-30: 92022-09-30: 30
the quarter ended 30 Sep 20228 earlier quartersnormal: 3.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 10 Dec 2022

Sensus Healthcare had 1.4M shares sold short in the 30 Nov 2022 report, 14× the same report last year.

This period
1.4M (the 30 Nov 2022 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
148K
How far from its usual level
+4.6
Same report last year
102K
History used
1,797 days
2021-11-15: 47K2021-11-30: 102K2021-12-15: 102K2022-01-14: 146K2022-01-31: 142K2022-02-15: 150K2022-02-28: 186K2022-03-15: 228K2022-03-31: 363K2022-04-14: 513K2022-04-29: 411K2022-05-13: 524K2022-05-31: 454K2022-06-15: 377K2022-06-30: 440K2022-07-15: 395K2022-07-29: 305K2022-08-15: 381K2022-08-31: 355K2022-09-15: 451K2022-09-30: 548K2022-10-14: 746K2022-10-31: 863K2022-11-15: 769K2022-11-30: 1.4M
the 30 Nov 2022 report24 earlier reportsnormal: 379K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Dec 2022

Sensus Healthcare had 1.5M shares sold short in the 15 Dec 2022 report, 14× the same report last year.

This period
1.5M (the 15 Dec 2022 report)
Normal report (median of 24 earlier)
388K
Typical spread (median absolute deviation)
148K
How far from its usual level
+4.9
Same report last year
102K
History used
1,812 days
2021-11-30: 102K2021-12-15: 102K2022-01-14: 146K2022-01-31: 142K2022-02-15: 150K2022-02-28: 186K2022-03-15: 228K2022-03-31: 363K2022-04-14: 513K2022-04-29: 411K2022-05-13: 524K2022-05-31: 454K2022-06-15: 377K2022-06-30: 440K2022-07-15: 395K2022-07-29: 305K2022-08-15: 381K2022-08-31: 355K2022-09-15: 451K2022-09-30: 548K2022-10-14: 746K2022-10-31: 863K2022-11-15: 769K2022-11-30: 1.4M2022-12-15: 1.5M
the 15 Dec 2022 report24 earlier reportsnormal: 388K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Nov 2026Insiders change

    had 3 insiders buy $260K of its shares on the open market within 30 days (3 filings).

    Who bought: Sardano Joseph C, Sachetta Eric, Cornish Megan.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $260K
    Window
    20 Oct 2026 to 19 Nov 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  2. 19 Nov 2026Insiders record

    Cornish Megan (director) bought 2,200 shares of SRTS ($5,016)

  3. 19 Nov 2026Insiders record

    Sachetta Eric (director) bought 81,575 shares of SRTS ($182,973)

  4. 17 Nov 2026Insiders record

    Sardano Joseph C (CHIEF EXECUTIVE OFFICER) bought 30,000 shares of SRTS ($72,108)

  5. 1 Sep 2026Insiders record

    Sachetta Eric (director) bought 64,841 shares of SRTS ($225,783) (dated 31 Aug 2026)

  6. 29 Aug 2026Insiders record

    Sachetta Eric (director) bought 20,633 shares of SRTS ($66,681) (dated 28 Aug 2026)

  7. 26 Aug 2026Insiders record

    Sachetta Eric (director) bought 34,697 shares of SRTS ($112,765) (dated 25 Aug 2026)

  8. 25 Aug 2026Insiders record

    Sachetta Eric (director) bought 31,000 shares of SRTS ($97,870) (dated 24 Aug 2026)

  9. 25 Aug 2026Insiders record

    Sardano Joseph C (CHIEF EXECUTIVE OFFICER) bought 20,000 shares of SRTS ($60,400) (dated 24 Aug 2026)

  10. 13 May 2026Insiders record

    Sachetta Eric (director) bought 1,500 shares of SRTS ($5,010) (dated 12 May 2026)

  11. 27 Feb 2026Insiders record

    Sachetta Eric (director) bought 2,000 shares of SRTS ($7,620) (dated 26 Feb 2026)

  12. 6 Feb 2026Lobbying record

    SENSUS HEALTHCARE, INC.: lobbying engagement terminated (CAPITOL ADVOCACY & GOVERNMENT AFFAIRS, LLC) (dated 3 Nov 2025)

  13. 20 Jan 2026Filings record

    Changed its auditor

  14. 17 Jan 2026Lobbying record

    CAPITOL ADVOCACY & GOVERNMENT AFFAIRS, LLC (ON BEHALF OF SENSUS HEALTHCARE): lobbying engagement terminated (BRIAN GLACKIN & ASSOCIATES LLC) (dated 31 Dec 2025)

  15. 10 Jan 2026Filings record

    Director or officer change (dated 9 Jan 2026)

  16. 22 Nov 2025Insiders record

    Sachetta Eric (director) bought 7,000 shares of SRTS ($27,510) (dated 21 Nov 2025)

  17. 21 Nov 2025Insiders change

    had 3 insiders buy $120K of its shares on the open market within 30 days (4 filings).

    Who bought: Sardano Michael, Sardano Joseph C, Sachetta Eric.

    See the evidence (4 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    4
    Total bought
    $120K
    Window
    22 Oct 2025 to 21 Nov 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  18. 21 Nov 2025Insiders record

    Sachetta Eric (director) bought 2,500 shares of SRTS ($11,250) (dated 20 Nov 2025)

  19. 20 Nov 2025Insiders record

    Sardano Michael (PRESIDENT AND GENERAL COUNSEL) bought 1,000 shares of SRTS ($3,800) (dated 19 Nov 2025)

  20. 20 Nov 2025Insiders record

    Sardano Joseph C (CHIEF EXECUTIVE OFFICER) bought 25,000 shares of SRTS ($100,750) (dated 19 Nov 2025)

  21. 19 Nov 2025Insiders record

    Sardano Michael (PRESIDENT AND GENERAL COUNSEL) bought 2,000 shares of SRTS ($4,286) [amended] (dated 18 Nov 2025)

  22. 14 Nov 2025Insiders record

    Sardano Michael (PRESIDENT AND GENERAL COUNSEL) bought 2,000 shares of SRTS ($4,263) [amended] (dated 13 Nov 2025)

  23. 13 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 13 Nov 2025Filings record

    Director or officer change

  25. 13 Nov 2025Insiders record

    Sardano Michael (PRESIDENT AND GENERAL COUNSEL) bought 1,000 shares of SRTS ($4,260) (dated 12 Nov 2025)

  26. 15 Aug 2025Insiders record

    Sardano Michael (PRESIDENT AND GENERAL COUNSEL) bought 1,000 shares of SRTS ($3,370) (dated 14 Aug 2025)

  27. 18 Jul 2025Lobbying record

    CAPITOL ADVOCACY & GOVERNMENT AFFAIRS, LLC (ON BEHALF OF SENSUS HEALTHCARE): new lobbying registration (BRIAN GLACKIN & ASSOCIATES LLC) (dated 9 Jun 2025)

  28. 9 Jul 2025Lobbying record

    SENSUS HEALTHCARE, INC.: new lobbying registration (CAPITOL ADVOCACY & GOVERNMENT AFFAIRS, LLC) (dated 9 Jun 2025)

  29. 27 Feb 2025Short interest and volume change

    had 1.2M shares sold short in the 14 Feb 2025 report, 24× the same report last year.

    Same report last year: 49K; its normal report is 458K.

    See the evidence
    This period
    1.2M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    458K
    Typical spread (median absolute deviation)
    102K
    How far from its usual level
    +4.8
    Same report last year
    49K
    History used
    2,604 days
    2024-02-15: 49K2024-02-29: 25K2024-03-15: 66K2024-03-28: 33K2024-04-15: 33K2024-04-30: 31K2024-05-15: 437K2024-05-31: 394K2024-06-14: 390K2024-06-28: 410K2024-07-15: 440K2024-07-31: 450K2024-08-15: 469K2024-08-30: 466K2024-09-13: 491K2024-09-30: 532K2024-10-15: 586K2024-10-31: 536K2024-11-15: 594K2024-11-29: 486K2024-12-13: 584K2024-12-31: 1.2M2025-01-15: 1.4M2025-01-31: 1.5M2025-02-14: 1.2M
    the 14 Feb 2025 report24 earlier reportsnormal: 458K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 12 Feb 2025Short interest and volume change

    had 1.5M shares sold short in the 31 Jan 2025 report, 41× the same report last year.

    Same report last year: 38K; its normal report is 445K.

    See the evidence
    This period
    1.5M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    445K
    Typical spread (median absolute deviation)
    115K
    How far from its usual level
    +6.5
    Same report last year
    38K
    History used
    2,590 days
    2024-01-31: 38K2024-02-15: 49K2024-02-29: 25K2024-03-15: 66K2024-03-28: 33K2024-04-15: 33K2024-04-30: 31K2024-05-15: 437K2024-05-31: 394K2024-06-14: 390K2024-06-28: 410K2024-07-15: 440K2024-07-31: 450K2024-08-15: 469K2024-08-30: 466K2024-09-13: 491K2024-09-30: 532K2024-10-15: 586K2024-10-31: 536K2024-11-15: 594K2024-11-29: 486K2024-12-13: 584K2024-12-31: 1.2M2025-01-15: 1.4M2025-01-31: 1.5M
    the 31 Jan 2025 report24 earlier reportsnormal: 445K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 11 Feb 2025Insiders record

    Sardano Michael (PRESIDENT AND GENERAL COUNSEL) bought 1,000 shares of SRTS ($5,950) (dated 10 Feb 2025)

  32. 11 Feb 2025Insiders record

    Rampolla Javier (CHIEF FINANCIAL OFFICER) bought 501 shares of SRTS ($2,981) (dated 10 Feb 2025)

  33. 28 Jan 2025Short interest and volume change

    had 1.4M shares sold short in the 15 Jan 2025 report, 35× the same report last year.

    Same report last year: 39K; its normal report is 439K.

    See the evidence
    This period
    1.4M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    439K
    Typical spread (median absolute deviation)
    121K
    How far from its usual level
    +5.1
    Same report last year
    39K
    History used
    2,574 days
    2024-01-12: 39K2024-01-31: 38K2024-02-15: 49K2024-02-29: 25K2024-03-15: 66K2024-03-28: 33K2024-04-15: 33K2024-04-30: 31K2024-05-15: 437K2024-05-31: 394K2024-06-14: 390K2024-06-28: 410K2024-07-15: 440K2024-07-31: 450K2024-08-15: 469K2024-08-30: 466K2024-09-13: 491K2024-09-30: 532K2024-10-15: 586K2024-10-31: 536K2024-11-15: 594K2024-11-29: 486K2024-12-13: 584K2024-12-31: 1.2M2025-01-15: 1.4M
    the 15 Jan 2025 report24 earlier reportsnormal: 439K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 14 Jan 2025Short interest and volume change

    had 1.2M shares sold short in the 31 Dec 2024 report, 35× the same report last year.

    Same report last year: 34K; its normal report is 424K.

    See the evidence
    This period
    1.2M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    424K
    Typical spread (median absolute deviation)
    136K
    How far from its usual level
    +3.9
    Same report last year
    34K
    History used
    2,559 days
    2023-12-29: 34K2024-01-12: 39K2024-01-31: 38K2024-02-15: 49K2024-02-29: 25K2024-03-15: 66K2024-03-28: 33K2024-04-15: 33K2024-04-30: 31K2024-05-15: 437K2024-05-31: 394K2024-06-14: 390K2024-06-28: 410K2024-07-15: 440K2024-07-31: 450K2024-08-15: 469K2024-08-30: 466K2024-09-13: 491K2024-09-30: 532K2024-10-15: 586K2024-10-31: 536K2024-11-15: 594K2024-11-29: 486K2024-12-13: 584K2024-12-31: 1.2M
    the 31 Dec 2024 report24 earlier reportsnormal: 424K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 13 Nov 2024Short interest and volume change

    had 536K shares sold short in the 31 Oct 2024 report, 9.8× the same report last year.

    Same report last year: 55K; its normal report is 67K.

    See the evidence
    This period
    536K (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    67K
    Typical spread (median absolute deviation)
    42K
    How far from its usual level
    +7.6
    Same report last year
    55K
    History used
    2,498 days
    2023-10-31: 55K2023-11-15: 53K2023-11-30: 67K2023-12-15: 25K2023-12-29: 34K2024-01-12: 39K2024-01-31: 38K2024-02-15: 49K2024-02-29: 25K2024-03-15: 66K2024-03-28: 33K2024-04-15: 33K2024-04-30: 31K2024-05-15: 437K2024-05-31: 394K2024-06-14: 390K2024-06-28: 410K2024-07-15: 440K2024-07-31: 450K2024-08-15: 469K2024-08-30: 466K2024-09-13: 491K2024-09-30: 532K2024-10-15: 586K2024-10-31: 536K
    the 31 Oct 2024 report24 earlier reportsnormal: 67K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 25 Oct 2024Short interest and volume change

    had 586K shares sold short in the 15 Oct 2024 report, 23× the same report last year.

    Same report last year: 26K; its normal report is 60K.

    See the evidence
    This period
    586K (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    60K
    Typical spread (median absolute deviation)
    35K
    How far from its usual level
    +10.2
    Same report last year
    26K
    History used
    2,482 days
    2023-10-13: 26K2023-10-31: 55K2023-11-15: 53K2023-11-30: 67K2023-12-15: 25K2023-12-29: 34K2024-01-12: 39K2024-01-31: 38K2024-02-15: 49K2024-02-29: 25K2024-03-15: 66K2024-03-28: 33K2024-04-15: 33K2024-04-30: 31K2024-05-15: 437K2024-05-31: 394K2024-06-14: 390K2024-06-28: 410K2024-07-15: 440K2024-07-31: 450K2024-08-15: 469K2024-08-30: 466K2024-09-13: 491K2024-09-30: 532K2024-10-15: 586K
    the 15 Oct 2024 report24 earlier reportsnormal: 60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 10 Oct 2024Short interest and volume change

    had 532K shares sold short in the 30 Sep 2024 report, 11× the same report last year.

    Same report last year: 47K; its normal report is 54K.

    See the evidence
    This period
    532K (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    54K
    Typical spread (median absolute deviation)
    25K
    How far from its usual level
    +9.6
    Same report last year
    47K
    History used
    2,467 days
    2023-09-29: 47K2023-10-13: 26K2023-10-31: 55K2023-11-15: 53K2023-11-30: 67K2023-12-15: 25K2023-12-29: 34K2024-01-12: 39K2024-01-31: 38K2024-02-15: 49K2024-02-29: 25K2024-03-15: 66K2024-03-28: 33K2024-04-15: 33K2024-04-30: 31K2024-05-15: 437K2024-05-31: 394K2024-06-14: 390K2024-06-28: 410K2024-07-15: 440K2024-07-31: 450K2024-08-15: 469K2024-08-30: 466K2024-09-13: 491K2024-09-30: 532K
    the 30 Sep 2024 report24 earlier reportsnormal: 54K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 11 Sep 2024Filings record

    Changed its auditor

  39. 31 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 31 May 2024Filings record

    Director or officer change (dated 30 May 2024)

Showing the newest 40 of 91 entries; narrow the window or the kind of data to see older ones.

Not listed: 195 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001494891
Ticker
SRTS
Domain
sensushealthcare.com
Hq location
FL|BOCA RATON|33487 (1 unverified)
Lobbying client
capitol advocacy and government affairs llc on behalf of sensus healthcare, sensus healthcare
Name
Sensus Healthcare, Inc
  • Federal lobbying disclosures (LDA)10 records, 53 data points20 Nov 2013 to 31 Dec 2025
  • SEC Form 13F institutional holdings378 data points30 Jun 2016 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)126 records4 Jan 2016 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)832 data points31 Dec 2014 to 10 Nov 2026
  • SEC Form 4 insider transactions124 records, 200 data points17 Aug 2016 to 19 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4172 data points1 Aug 2018 to 20 Nov 2026